HealthDay News — The U.S. Food and Drug Administration has approved emergency use of the first COVID-19 test that enables patients to take samples at home.

The authorization is for the Laboratory Corporation of America (LabCorp) COVID-19 RT-PCR Test to test samples self-collected by patients at home using LabCorp’s Pixel by LabCorp COVID-19 Test home collection kit, the agency explained.

For “tests that include home sample collection, we worked with LabCorp to ensure the data demonstrated from at-home patient sample collection is as safe and accurate as sample collection at a doctor’s office, hospital, or other testing site. With this action, there is now a convenient and reliable option for patient sample collection from the comfort and safety of their home,” FDA Commissioner Stephen Hahn, M.D., said in an agency news release.

Continue Reading

Patients use a self-collection kit that contains nasal swabs and saline. After self-swabbing to collect their nasal sample, patients mail their sample in an insulated package to a LabCorp lab for testing.

LabCorp plans to make the home collection kits available to consumers in most states, with a doctor’s order, in the coming weeks, according to the FDA. It said this authorization only applies to the LabCorp COVID-19 RT-PCR Test for at-home collection of nasal swab specimens using the Pixel by LabCorp COVID-19 home collection kit and is not a general authorization for at-home collection of patient samples using other collection swabs, media, or tests or for tests fully conducted at home.

Related Articles

More Information